Researchers reported a gene therapy approach that combines a poly-(HA-GMA) hydrogel with AAV8-sTβRII to reduce late-stage fibrosis and minimize skin scarring. The report emphasized that the delivery system targets scar-related pathways without disrupting early wound-healing steps. By using the hydrogel for localized delivery alongside AAV-mediated modulation of fibrosis signaling, the study aims to address a major clinical unmet need—scar prevention that can reduce functional and cosmetic morbidity after injury. For the gene-therapy and regenerative medicine field, the work highlights delivery-engineering progress: biologic effects are increasingly being tied to biomaterial systems designed to preserve the natural healing timeline.